Retatrutide vs Mounjaro vs Ozempic
A plain-language comparison of retatrutide, tirzepatide and semaglutide for readers researching metabolic health, weight-management treatments and clinic options in Thailand.
Important medical status
Retatrutide is an investigational medicine. Public availability depends on clinical trial completion, regulatory review, local rules and professional medical assessment.
This comparison is for educational information only. It does not provide medical advice, sell medication, offer prescriptions or recommend treatment.
How These Treatments Are Commonly Discussed
Retatrutide, Mounjaro and Ozempic are often discussed together because they are related to metabolic health, appetite regulation and weight-management conversations. However, they are not the same treatment, and their approval status, use, risks and availability can differ.
Retatrutide
Retatrutide is being studied as a once-weekly triple hormone receptor agonist involving GIP, GLP-1 and glucagon receptor activity.
Mounjaro
Mounjaro is the brand name for tirzepatide. It is commonly described as a GIP and GLP-1 receptor agonist where approved for specific indications.
Ozempic
Ozempic is the brand name for semaglutide. It is commonly described as a GLP-1 receptor agonist where approved for specific indications.
Comparison Table
Use this table as a high-level educational overview. It is not a treatment recommendation. Suitability depends on medical history, current medication, risk factors, regulatory status and professional assessment.
| Category | Retatrutide | Mounjaro / Tirzepatide | Ozempic / Semaglutide |
|---|---|---|---|
| General type | Investigational triple hormone receptor agonist. | Dual GIP and GLP-1 receptor agonist. | GLP-1 receptor agonist. |
| Receptor activity | GIP, GLP-1 and glucagon receptor activity. | GIP and GLP-1 receptor activity. | GLP-1 receptor activity. |
| Research / approval status | Under clinical development and regulatory review. | Approved in many markets for specific indications; status varies by country. | Approved in many markets for specific indications; status varies by country. |
| Availability | Public availability depends on trial completion, regulatory decisions and local rules. | Availability depends on local approval, prescription rules and clinic or pharmacy policy. | Availability depends on local approval, prescription rules and clinic or pharmacy policy. |
| Medical supervision | Should be discussed only with qualified healthcare professionals. | Prescription-only where approved and requires medical assessment. | Prescription-only where approved and requires medical assessment. |
| Consumer caution | Be cautious with online products marketed as “research peptides” or unverified retatrutide. | Use only through appropriate medical and pharmacy channels. | Use only through appropriate medical and pharmacy channels. |
Why Retatrutide Is Different
The main reason retatrutide is discussed separately from Mounjaro and Ozempic is its investigational triple receptor approach. While Ozempic is commonly described as GLP-1 based and Mounjaro as GIP/GLP-1 based, retatrutide is being studied for activity across GIP, GLP-1 and glucagon receptors.
GLP-1
GLP-1 receptor activity is commonly discussed in relation to appetite, glucose regulation and metabolic treatment research.
GIP
GIP receptor activity is part of the mechanism discussed with dual agonist and triple agonist approaches.
Glucagon
Glucagon receptor activity is one of the features that makes retatrutide different from GLP-1-only treatments.
About “GLP-3” and peptide marketing
Retatrutide is sometimes discussed online in simplified or inaccurate ways. “GLP-3” is not a scientifically accurate classification. Retatrutide may also be marketed online as a “research peptide,” but consumers should be cautious with products that are not approved, verified or supplied through appropriate medical channels.
What This Means for People in Thailand
People researching these treatments in Thailand should focus on medical guidance, legal availability, pricing transparency and follow-up support. The right next step is not simply finding the lowest price, but understanding whether a clinic can explain suitability, safety and current availability clearly.
Ask about status
Ask whether the clinic can explain current availability, regulatory status and whether a treatment can legally be discussed or provided.
Ask about safety
Ask what medical history, lab work or screening is required before any treatment discussion.
Ask about total cost
Ask whether pricing includes consultation, follow-up, monitoring, lab work and support.
Frequently Asked Questions
Is retatrutide the same as Mounjaro?
No. Mounjaro is tirzepatide, commonly described as a GIP and GLP-1 receptor agonist. Retatrutide is being studied as a triple hormone receptor agonist involving GIP, GLP-1 and glucagon receptor activity.
Is retatrutide the same as Ozempic?
No. Ozempic is semaglutide, commonly described as a GLP-1 receptor agonist. Retatrutide is investigational and has a different receptor profile.
Which treatment is best?
This page does not recommend one treatment over another. Suitability depends on medical history, current medication, risk factors, regulatory status and professional medical assessment.
Can clinics in Thailand provide these treatments?
Availability depends on regulatory status, clinic policy, prescription requirements, medical assessment and whether a treatment is legally available at the time of consultation.
Why do some websites call retatrutide a peptide?
Retatrutide is a synthetic peptide, but it is also an investigational medicine under clinical development. Products marketed online as “research peptides” may not be approved, verified or safe for human use.
Important safety reminder
Avoid websites or sellers that promise guaranteed results, avoid medical screening, refuse to explain regulatory status, or market unverified products as safe for human use.
Any health-related decision should be discussed with a qualified healthcare professional.